| scholarly article | Q13442814 |
| P50 | author | Alexandros Briasoulis | Q58119200 |
| P2093 | author name string | Rafael Fonseca | |
| Christopher Strouse | |||
| Yogesh Jethava | |||
| P2860 | cites work | Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase | Q28577236 |
| Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. | Q30493710 | ||
| Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. | Q33155937 | ||
| Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens | Q33508070 | ||
| Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study | Q33734406 | ||
| Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans | Q34415207 | ||
| Diagnosis and management of the cardiac amyloidoses | Q34454122 | ||
| EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers | Q34656396 | ||
| Amyloidosis: pathogenesis and new therapeutic options. | Q35111771 | ||
| Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. | Q35579434 | ||
| Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative? | Q35755799 | ||
| Current Concepts of Cardiac Amyloidosis: Diagnosis, Clinical Management, and the Need for Collaboration | Q36303274 | ||
| Transthyretin (TTR) cardiac amyloidosis | Q36408438 | ||
| Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience | Q36498412 | ||
| Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements | Q36910372 | ||
| (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses | Q37054790 | ||
| Transthyretin: more than meets the eye. | Q37576502 | ||
| 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. | Q37964168 | ||
| A review of the United States experience with combined heart-liver transplantation. | Q38039454 | ||
| Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. | Q38343098 | ||
| Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. | Q38370866 | ||
| Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology | Q38532386 | ||
| Heart transplantation in cardiac amyloidosis | Q39172346 | ||
| Ischemic heart disease secondary to amyloidosis of intramyocardial arteries | Q39892131 | ||
| Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease | Q40977805 | ||
| Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis | Q42288032 | ||
| Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis | Q42292795 | ||
| Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. | Q43050098 | ||
| The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis | Q44163512 | ||
| Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis | Q44248482 | ||
| A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. | Q44254874 | ||
| Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis | Q44657473 | ||
| Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study | Q45331104 | ||
| Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis | Q46463218 | ||
| Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines | Q46502103 | ||
| Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis | Q47234415 | ||
| Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement | Q47878487 | ||
| Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis | Q48172828 | ||
| Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis | Q48382207 | ||
| Incidence of amyloidosis over 3 years: the AMYPRO study. | Q48751142 | ||
| Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis | Q49546522 | ||
| Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone | Q49912616 | ||
| Abdominal Fat Pad Excisional Biopsy for the Diagnosis and Typing of Systemic Amyloidosis | Q50043841 | ||
| Rapid hematological responses improve outcomes in patients with very advanced (Stage IIIb) cardiac immunoglobulin light chain amyloidosis. | Q50158376 | ||
| Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis | Q52716575 | ||
| The six-minute walk test in patients with AL amyloidosis: a single centre case series. | Q53402595 | ||
| Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. | Q53463848 | ||
| Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy | Q56340333 | ||
| Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis | Q58030559 | ||
| The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients | Q58190652 | ||
| Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? | Q58266503 | ||
| Deferred autologous stem cell transplantation in systemic AL amyloidosis | Q58609453 | ||
| Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis | Q60976498 | ||
| Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis | Q67271832 | ||
| Orthotopic liver transplantation for hepatic-based metabolic disorders | Q72625294 | ||
| Symptomatic conduction system disease in cardiac amyloidosis | Q73943156 | ||
| Noninvasive diagnosis of biopsy-proven cardiac amyloidosis | Q79761534 | ||
| Non-invasive predictors of survival in cardiac amyloidosis | Q79916231 | ||
| Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis | Q82552434 | ||
| Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis | Q88134600 | ||
| Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure | Q88514454 | ||
| Myocardial Edema and Prognosis in Amyloidosis | Q89180189 | ||
| Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis | Q89419396 | ||
| Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis | Q89419413 | ||
| Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation | Q90283543 | ||
| Clinical and endoscopic manifestations of gastrointestinal amyloidosis: a case series | Q90622988 | ||
| Grading cardiac response in AL amyloidosis: implications for relapse and survival | Q90657294 | ||
| Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p | Q90925994 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 567-574 | |
| P577 | publication date | 2019-07-01 | |
| P1433 | published in | Journal of Geriatric Cardiology | Q15765238 |
| P1476 | title | Approach to a patient with cardiac amyloidosis | |
| P478 | volume | 16 |
Search more.